Gene therapy may treat obesity
By Times of India,
Times of India
| 03. 10. 2009
Alarmed by the rise in obesity, researchers are examining the possibility of injecting a gene directly into one of the critical feeding and weight control centres of the brain.
"Obesity significantly increases the risk for diabetes, cardiovascular disease, stroke and some cancers," said Matthew During, the study's co-author and professor at Ohio State University Medical Centre.
"Our findings represent a promising new treatment for obesity that could ultimately provide a much safer and more effective approach than some conventional therapies," he said.
Scientists have discovered that a particular gene, BDNF, when active in the hypothalamus, can result in improved insulin sensitivity, reduced fat mass and weight loss.
Lei Cao, a co-author and assistant professor of molecular virology, immunology and medical genetics, said the study involved injecting the BDNF gene in normal mice, diabetic mice and mice fed with a high fat diet, to determine how the gene transfer would affect their weight.
"The gene was active in the overweight mice but as they lost weight, the gene expression was essentially 'dialed down,' using a novel RNA interference approach, thus stopping...
Related Articles
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Miguel Muñoz, Cadena SER | 08.04.2026
"Para ellos, una familia numerosa no solo es una preferencia personal, sino que es una obligación. Creen que tener tantos hijos como sea posible es necesario para evitar un futuro apocalíptico", aseguraba Xavier Orri, periodista y cofundador de Página Internacional...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...